Iqvia Holdings Inc.
IQVIA Reports Q4 2023 Financial Results and 2024 Guidance
Summary
IQVIA Holdings Inc. announced its financial results for the fourth-quarter and full-year 2023, reporting a revenue of $3,868 million for Q4 and $14,984 million for the full year. GAAP Net Income was $469 million for Q4 and $1,358 million for 2023. The company also provided full-year 2024 guidance with revenue expected between $15,400 million and $15,650 million, Adjusted EBITDA between $3,700 million and $3,800 million, and Adjusted Diluted Earnings per Share between $10.95 and $11.25.
Profitelligence Alerts
Get alerts for IQV
Be first to know when Iqvia Holdings Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Iqvia Holdings Inc.
Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.
Official SEC Documents
Advertisement